Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Satyam Infoway Ltd-(Nasdaq:SIFY) -- Ignore unavailable to you. Want to Upgrade?

To: Mohan Marette who wrote (1291)	3/21/2000 8:31:00 AM
From: Mohan Marette	Read Replies (1) \| Respond to of 1471

OT Ranbaxy gets FDA approval for sale of drugs in U.S. ranbaxy.com 21-03-2000 17:13:52 Pharmaceuticals firm Ranbaxy Laboratories has got approval from the U.S. Food and Drug Administration (FDA) to market Pentazocine (50 mg) and Naloxone (0.5 mg) tablets in the United States. In a statement, Ranbaxy said a statement that it is the first Indian company to get approval in this product category. The formulation is used for post-operative surgeries and acute pains associated with ailments like cancer, it said. The firm said it targets an average of 10 abbreviated new drug application (ANDA) filings annually in the U.S. It has so far filed 26 ANDAs and received a total of 16 approvals for eight molecules, it said. Ranbaxy shares ended today Rs6 down at Rs648 on the Bombay Stock Exchange. Source: Reuters